ONP 001 - OmniNano Pharmaceuticals
Alternative Names: ONP-001 - OmniNano PharmaceuticalsLatest Information Update: 04 Jul 2025
At a glance
- Originator OmniNano Pharmaceuticals
- Class Alkaloids; Antineoplastics; Paclitaxels; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Hedgehog cell signalling pathway inhibitors; Immunosuppressants; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Adenocarcinoma; Liver cancer
Most Recent Events
- 25 Apr 2025 Preclinical trials in Adenocarcinoma in USA (IV) prior to April 2025
- 25 Apr 2025 Preclinical trials in Liver cancer in USA (IV) prior to April 2025
- 25 Apr 2025 Pharmacodynamics and adverse event data from a preclinical study in Liver cancer and Adenocarcinoma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)